Oral budesonide for induction of remission in ulcerative colitis

Cochrane Reviews, 10/26/2010

The purpose of this review was to examine the effectiveness of oral budesonide for the treatment of ulcerative colitis. The authors found three studies that were eligible for inclusion in this review. Although the side–effect profile of budesonide is better than that of prednisolone, there is no evidence to recommend the use of oral budesonide for active ulcerative colitis. There are 2 large ongoing trials which will provide further information regarding the potential effectiveness of oral budesonide for the treatment of active ulcerative colitis. One of the included studies compared budesonide with mesalamine (a 5–ASA drug). This study provides high quality evidence that mesalamine is superior to budesonide for the treatment of active ulcerative colitis.

Print Article Summary Cat 2 CME Report